Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group-Reference-Cited by-同舟云学术

Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group

Published:2016-05-11 Issue:7 Volume:91 Page:681-686
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am. J. Hematol.

Author:

Rotunno Giada¹,Pacilli Annalisa¹,Artusi Valentina²,Rumi Elisa³⁴,Maffioli Margherita⁵,Delaini Federica⁶,Brogi Giada¹,Fanelli Tiziana¹⁷,Pancrazzi Alessandro¹,Pietra Daniela³,Bernardis Isabella²,Belotti Clara⁶,Pieri Lisa¹,Sant'Antonio Emanuela¹,Salmoiraghi Silvia⁶,Cilloni Daniela⁸,Rambaldi Alessandro⁶,Passamonti Francesco⁵,Barbui Tiziano⁹,Manfredini Rossella¹⁰,Cazzola Mario³,Tagliafico Enrico²,Vannucchi Alessandro M.¹,Guglielmelli Paola¹

Affiliation:

1. CRIMM-Center for Research and Innovation of Myeloproliferative Neoplasms, AOU Careggi, Department of Experimental and Clinical Medicine, DENOTHE Excellence Center; University of Florence; Florence Italy

2. Center for Genome Research, and Department of Medical and Surgical Sciences; University of Modena and Reggio Emilia; Modena, Italy

3. Department of Hematology Oncology; Fondazione IRCCS Policlinico San Matteo; Pavia Italy

4. Department of Molecular Medicine; University of Pavia; Pavia Italy

5. Ospedale Di Circolo - Fondazione Macchi; University of Insubria; Varese Italy

6. Hematology and BMT Unit; ASST Papa Giovanni XXIII; Bergamo Italy

7. University of Siena; Siena Italy

8. Department of Clinical and Biological Sciences University of Turin; San Luigi Hospital Turin; Turin Italy

9. FROM Research Foundation; Ospedale Papa Giovanni XXIII; Bergamo Italy

10. Department of Life Sciences, Centre for Regenerative Medicine; University of Modena and Reggio Emilia; Modena Italy

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ajh.24377/fullpdf

Reference38 articles.

1. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT);Mesa;Leuk Res,2007

2. Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: A literature review of incidence and risk factors;Cerquozzi;Blood Cancer J,2015

3. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A consensus statement from the international working group for myelofibrosis research and treatment;Barosi;Leukemia,2008

4. The clinical benefit of ruxolitinib across patient subgroups: Analysis of a placebo-controlled, phase III study in patients with myelofibrosis;Verstovsek;Br J Haematol,2013

5. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis;Cervantes;Blood,2013

Cited by 77 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. One thousand patients with essential thrombocythemia: the Florence-CRIMM experience;Blood Cancer Journal;2024-01-18

2. JAK2 V617F mutation and associated chromosomal alterations in primary and secondary myelofibrosis and post-HCT outcomes;Blood Advances;2023-12-14

3. Myeloproliferative Neoplasms: Contemporary Review and Molecular Landscape;International Journal of Molecular Sciences;2023-12-12

4. Molecular diagnostic criteria of myeloproliferative neoplasms;Expert Review of Molecular Diagnostics;2023-11-24

5. Real-world clinical characteristics of post-essential thrombocythemia and post-polycythemia vera myelofibrosis;Annals of Hematology;2023-11-10